Frontage Acquires Majority Stake in Wuhan Heyan Biomedical, a CRO
publication date: Sep 9, 2021
Frontage Shanghai, a division of US-China CRO Frontage Holdings, acquired a 70% stake in Wuhan Heyan Biomedical Technology, a discovery CRO. Heyan offers target-based in vitro pharmacodynamic screening and early pharmacological pharmacodynamic evaluation services for biologic drug discovery. Its technical services include screening of drug targets, customized biological assay development and detection services. Frontage, which is majority owned by Hangzhou's TigerMed, offers drug evaluation, product development/CMC and clinical services. More details....
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.